Skip to main content

letter

. 1982 May;13(5):747–750. doi: 10.1111/j.1365-2125.1982.tb01452.x

The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

M J Vandenburg, P Wright, J Holmes, H J Rogers, R A Ahmad

PMCID: PMC1402085 PMID: 7082547

747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Ahmad R. A., Rogers H. J. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin Pharmacol. 1980 Feb;17(2):129–133. doi: 10.1007/BF00562621. [DOI] [PubMed] [Google Scholar]
Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
Hunyor S. N. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype. Aust N Z J Med. 1975 Dec;5(6):530–536. doi: 10.1111/j.1445-5994.1975.tb03857.x. [DOI] [PubMed] [Google Scholar]
Kalowski S., Hua A. S., Whitworth J. A., Kincaid-Smith P. Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study. Med J Aust. 1979 Oct 20;2(8):439–440. [PubMed] [Google Scholar]
Talseth T., Fauchald P., Pape J. F. Hydralazine slow-release: observations on serum profile and clinical efficacy in man. Curr Ther Res Clin Exp. 1977 Feb;21(2):157–168. [PubMed] [Google Scholar]
Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972 May-Jun;13(3):420–425. doi: 10.1002/cpt1972133420. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES